Rinvoq (upadacitinib) is a prescription drug used to treat certain autoimmune conditions. This drug can interact with some medications, vaccines, and supplements. For example, Rinvoq can interact ...

Routinely monitor liver enzymes; interrupt therapy if ALT/AST elevated and drug-induced liver injury is suspected. Monitor lipids 12 weeks following initiation and manage hyperlipidemia.

Certain factors, such as the form of Rinvoq you’re prescribed, may determine whether you should take the drug during this time. If you may be or can become pregnant, it’s important to consider ...

The company needs Rinvoq and another new immunology drug – recently-approved psoriasis therapy Skyrizi (risankizumab) – to help offset the expected declines in Humira sales once biosimilar ...

A second stage of the study, which has yet to generate results, is looking at whether patients who achieve remission with Rinvoq can maintain that status while the drug is phased out. Rinvoq is a ...

Amgen saw no fewer than 10 of its medications post double-digit sales growth last year. AbbVie expects sales for Rinvoq and Skyrizi together to reach $31 billion as soon as 2027. Both ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

Those gains over January, when the drugs fell to third and fourth on the list, came even as spending dropped for both meds: AbbVie spent $34.8 million on Rinvoq’s TV ads and $27 million on ...

AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are ...

AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two treatments offset continuing falling sales of its ...

(American Journal of Gastroenterology) Real-world data confirmed the effectiveness of upadacitinib (Rinvoq) in Crohn's disease, with clinical remission achieved in 56% of patients at 6 months ...